John B Bender

US Patent:

6476034, Nov 5, 2002

Filed:

Jul 25, 2001

Appl. No.:

09/912710

Inventors:

Tao Wang - Middletown CT
Owen B. Wallace - Zionsville IN
Zhongxing Zhang - Madison CT
Nicholas A. Meanwell - East Hampton CT
John A. Bender - Rocky Hill CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31496

US Classification:

51425304, 544362

Abstract:

The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.

US Patent:

6632819, Oct 14, 2003

Filed:

Oct 10, 2002

Appl. No.:

10/268350

Inventors:

Tao Wang - Middletown CT
Owen B. Wallace - Zionsville IN
Zhongxing Zhang - Madison CT
Nicholas A. Meanwell - East Hampton CT
John A. Bender - Rocky Hill CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31496

US Classification:

51425304, 544362, 546113

Abstract:

The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.

US Patent:

6825201, Nov 30, 2004

Filed:

Apr 22, 2002

Appl. No.:

10/127256

Inventors:

Tao Wang - Middletown CT
Owen B. Wallace - Zionsville IN
Nicholas A. Meanwell - East Hampton CT
Zhongxing Zhang - Madison CT
John A. Bender - Middletown CT
John F. Kadow - Wallingford CT
Kap-Sun Yeung - Madison CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31496

US Classification:

51425406, 51425409, 51425304, 51425411, 51425213, 544362, 544371, 544373, 544376

Abstract:

The invention comprises substituted indole, azaindole and related heterocyclic amidopiperazine derivatives of general Formula I wherein: Q is âmay represent a bond; A is selected from the group consisting of C alkoxy, C alkyl, C cycloalkyl, phenyl, and heteroaryl; wherein said heteroaryl may be monocyclic or bicyclic and may be comprised of three to eleven atoms selected from the group consisting of C, N, NR , O, and S, and wherein each ring of said phenyl and heteroaryl is optionally substituted with one to five same or different substituents selected from the group consisting of R -R ; T is U is NR , O, or S; V is C(H) R , O or N(R ) W is CR or NR ; X is CR or NR ; Y is CR or NR ; Z is CR or NR ; k is or and m, n, and p are each independently , or provided that the sum of m, n, and p must equal or compositions thereof and their use as antiviral agents, particularly for treating HIV infection.

US Patent:

6900323, May 31, 2005

Filed:

Jul 16, 2003

Appl. No.:

10/621139

Inventors:

Tao Wang - Middletown CT, US
Owen B. Wallace - Zionsville IN, US
Zhongxing Zhang - Madison CT, US
Nicholas A. Meanwell - East Hampton CT, US
John A. Bender - Rocky Hill CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D471/04

US Classification:

546113

Abstract:

The invention comprises novel azaindole intermediate compounds useful in the preparation of compounds of the class of azaindole piperazine diamide derivatives, composition thereof and their use as anti-viral agents, and particularly for treating HIV infection.

US Patent:

7399758, Jul 15, 2008

Filed:

Aug 22, 2006

Appl. No.:

11/507731

Inventors:

Nicholas A. Meanwell - East Hampton CT, US
Robert G. Gentles - Wallingford CT, US
Min Ding - Glastonbury CT, US
John A. Bender - Middletown CT, US
John F. Kadow - Wallingford CT, US
Piyasena Hewawasam - Middletown CT, US
Thomas W. Hudyma - Durham CT, US
Xiaofan Zheng - Cheshire CT, US

International Classification:

A61P 31/00
A61K 31/55
C07D 223/14

US Classification:

51421401, 540576

Abstract:

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

US Patent:

7456166, Nov 25, 2008

Filed:

May 3, 2007

Appl. No.:

11/743921

Inventors:

John A. Bender - Middletown CT, US
Min Ding - Glastonbury CT, US
Robert G. Gentles - Wallingford CT, US
Piyasena Hewawasam - Middletown CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/55
A61P 31/00

US Classification:

51421401, 540576

Abstract:

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

US Patent:

7473688, Jan 6, 2009

Filed:

Sep 6, 2006

Appl. No.:

11/516435

Inventors:

Carl P. Bergstrom - Madison CT, US
John A. Bender - Middletown CT, US
Robert G. Gentles - Wallingford CT, US
Piyasena Hewawasam - Middletown CT, US
Thomas W. Hudyma - Durham CT, US
John F. Kadow - Wallingford CT, US
Scott W. Martin - Middletown CT, US
Alicia Regueiro-Ren - Middletown CT, US
Kap-Sun Yeung - Madison CT, US
Yong Tu - Cheshire CT, US
Xiaofan Zheng - Cheshire CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/55
A61P 31/00
C07D 223/14

US Classification:

51421401, 540576

Abstract:

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

US Patent:

7485633, Feb 3, 2009

Filed:

Mar 12, 2007

Appl. No.:

11/684710

Inventors:

Nicholas A. Meanwell - East Hampton CT, US
Robert G. Gentles - Wallingford CT, US
Min Ding - Glastonbury CT, US
John A. Bender - Middletown CT, US
John F. Kadow - Wallingford CT, US
Piyasena Hewawasam - Middletown CT, US
Thomas W. Hudyma - Durham CT, US
Xiaofan Zheng - Cheshire CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/55
A61P 31/00
C07D 223/14

US Classification:

51421401, 540576

Abstract:

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.